Clinical Trial Update: Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating darunavir/cobicistat and dolutegravir to maintain virologic suppression and reduce NRTI-associated toxicity has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Aids

Drugs mentioned

• Dolutegravir (dolutegravir)
• darunavir/cobicistat (darunavir/cobicistat)

Snippet

Sponsor: Stanford University | Conditions: HIV/AIDS | Phase 2, Phase 3 | Status: WITHDRAWN